Agenda - Healthcare Dealmaking Symposium (Deal Events)

The Deal
Thursday, November 26, 
9:06 am

Healthcare Dealmaking Symposium


7:30 a.m.   Breakfast and Registration
8:30-8:45 a.m.   Welcome and Opening Remarks
Robert Teitelman, Editor-in-ChiefThe Deal LLC
8:45-9:45 a.m.   Opening Panel: What's on the Healthcare Dealmaking Landscape for 2009 and Beyond?
Healthcare is a driving force in the global economy. With U.S. consumption 15% of the country's gross national product, far outpacing that of any other developed nations, demand continues to support investment and acquisition strategies. Combine this with an aging population here and abroad, there are significant deal opportunities for private and strategic investors. Distinguished panelists will talk about key trends dealmakers must know, growth opportunities and dealmaking strategies unwinding in the current economy.

Steven Elek III, Partner, Healthcare Transaction Services Leader, PricewaterhouseCoopers
Adam Berger, Managing Director, Head of M&A, Leerink Swann
Dr. Craig Frances, Managing Director, Summit Partners
Buddy Gumina, Partner, Head of U.S. Healthcare, Apax Partners LP
Keith Pagnani, Partner, Sullivan & Cromwell LLP 
Richard H. Stowe, General Partner, Health Enterprise Partners
9:45-10:30 a.m.   Panel: The Obama Administration: Immediate Steps in Regulation and Reforms
In this historic presidential year, how the Obama Administration addresses healthcare reform will drastically affect dealmaking decisions for years to come. What changes are ahead at the FDA? What opportunities will arise if universal healthcare takes form? Our panel of Washington insiders and healthcare reform experts will share their insights on the proposals and referendums circulating on Capital Hill.

William McConnell, Washington D.C. Bureau ChiefThe Deal LLC
David Balto, Senior FellowCenter For American Progress
Susan Berson, Senior Member, Health Law Practice, Mintz Levin
Dr. John G. Hunter, Clinical Associate Professor of SurgeryWeill Cornell Medical College and Special Advisor to the President for Patient Safety, Policies and Initiatives, American Association for Accreditation of Ambulatory Surgery Facilities
Oliver Marti, Managing Director/Portfolio Manager Healthcare, Columbus Circle Investors
Dr. Albert Waxman, CEO and Senior Managing MemberPsilos Group

10:30-10:45 a.m.   Networking Break
10:45-11:15 a.m.   Keynote
Sam Isaly, Founder and Managing Partner, OrbiMed Advisors
11:15-12:00 p.m.   Panel: Innovative Private Equity Fund Strategies - Growth Capital, Royalty Investing, Technology and Devices
Private investment in many aspects of healthcare, product development, delivery and administration, is anticipated to rise as government budgets are stressed in the economic crisis. They will discuss how deals are getting done in light of tight credit and what types of debt are available for healthcare deals. Panelists will also share various portfolio strategies and what factors matter most when making acquisitions and exits.

Aron Dantzig, Managing Director, Co-Head Healthcare GroupFortress Investments Drawbridge Special Opportunities Fund
Todd Davis, Co-founder and Managing Director, Cowen Healthcare Royalty Partners
Benjamin Edmands, Managing Director, CCMP Advisors, LLP
Tadd Wessel, Director, OrbiMed Advisors
12:00-1:30 p.m.   Networking Luncheon and Keynote with Bart Oates, Esq. Former Center for the New York Giants and San Francisco 49ers. Currently, the co-founder and General Counsel to All-Pro Title Group, LLC

Introduction by: 
Dr. Archie Roberts, Founder
Living Heart Foundation - CHN Network
1:30-2:15 p.m.   Panel: End of the Blockbuster Era: What's in the Pipeline
Many blockbuster drugs are approaching the generic cliff, regulatory reform is looming, and the price of developing new products is sky-high. With budgetary pressures on R&D, how does the pipeline get financed? How is the biotech-pharma partnership, one cornerstone of industry development, evolving? Which alternative financing vehicles are working, which aren't, and how will they be affected by the deepening recession? We'll also try to touch upon the disease areas and new technologies that big pharma can't afford to miss, either through acquisition or other means.

Alex Lash, Senior WriterThe Deal LLC
Chris Garabedian, Vice President of Corporate StrategyCelgene Corporation
Richard L. Manning, Director, Transactions Services Strategy Group, PricewaterhouseCoopers
Tom Perkins, Senior Vice President, Corporate Development,  Quintiles Transnational Corp. - Nova Quest
Fiona Schaeffer, Partner, Weil, Gotshal & Manges LLP 
2:15-3:00 p.m.   Panel: Cross-border Deals: Pharmaceuticals, Biotech and Devices Leading the Charge
Cross-border activity is on the rise allowing companies to access new markets. Hot targets include generic pharmaceutical manufacturers, biotech and medical devices. Emerging markets are attracting healthcare retailers and distributors. Will these trends continue? Experts in global transactions will share insights and observations from the field.

Alex Lash, Senior WriterThe Deal LLC
Dave Cummings, Managing PartnerAgile Equity
Dr. Annarie Lyles, Senior Vice President, Head of Business DevelopmentGenmab, Inc.
Michael Neuberger, Managing Director, Jefferies & Co.
3:00-3:45 p.m. Panel: Strategies for Distressed Investing and Turnaround Situations in Healthcare
This panel will discuss consolidation trends and cost containment among managed care, hospitals and REITS. With Medicare as the biggest "buyer" of healthcare services and its future payment ability in question, many companies may find the need to restructure, file for bankruptcy or brace for diminishing revenue streams.

Samuel Maizel, PartnerPachulski Stang Ziehl & Jones LLP
Patrick Hurst, Managing Director, Houlihan Lokey
Christopher Kersey, Managing Member and PartnerCamden Partners
Steve Krupa, Managing Member, Psilos Group  
Nathaniel M. Zilkha, Director, Kohlberg Kravis Roberts & Co.
3:45-4:15 p.m.   Keynote
4:15-6:30 p.m.   Networking Cocktail Reception

For more information on The Deal Events or to discuss speaking opportunities, please contact Martha Brown, or 212-313-9218.

*The Deal LLC reserves the right to alter the agenda of The Healthcare Dealmaking Symposium and/or substitute speakers without advance notice. This agenda remains the sole property of The Deal LLC, and may not be used to market or promote any other conference. Any such unauthorized distribution represents theft of property for which The Deal LLC will pursue any and all appropriate legal remedies.

footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg footspacer.jpg

©Copyright 2009, The Deal, LLC. All rights reserved. Please send all technical questions, comments or concerns to the Webmaster.